NeuroSense Therapeutics

growth-positive

NeuroSense Therapeutics Ltd., a late-clinical stage biotechnology company, has announced positive findings from its Phase-2b PARADIGM study. The study showed that their lead drug candidate, PrimeC, significantly reduced several Alzheimers disease-associated microRNAs, indicating a reduction in neuroinflammatory and neurodegenerative activity. These findings support PrimeCs potential as a disease-modifying therapy for Alzheimers disease. The study involved 68 participants with ALS, and PrimeC demonstrated the ability to slow disease progression beyond the standard ALS treatment. NeuroSense is advancing PrimeCs Phase 3 readiness program in ALS, aiming to address the significant unmet need for effective neurodegenerative disease treatments.

growth-positive

NeuroSense Therapeutics Ltd., a late-clinical stage biotechnology company, announced positive findings from its Phase-2b PARADIGM study for its lead drug candidate, PrimeC. The study showed that PrimeC significantly reduced several Alzheimers disease-associated microRNAs, indicating a reduction in neuroinflammatory and neurodegenerative activity. These results support PrimeCs potential as a disease-modifying therapy for Alzheimers disease. PrimeC is an extended-release oral formulation combining two FDA-approved drugs, ciprofloxacin and celecoxib, designed to target key mechanisms of ALS and Alzheimers disease. The findings will inform the design of future Alzheimers studies while advancing PrimeCs Phase 3 readiness program in ALS.

growth-negative

The article reports a decline in healthcare stocks on Wednesday afternoon, with the NYSE Health Care Index falling by 0.8%. This decline indicates a negative impact on the healthcare sector, though specific companies are not mentioned. The article is part of a premium news service, requiring a Silver or Gold subscription to access the full content. The decline in healthcare stocks is part of broader market movements, but further details are not provided in the excerpt.

growth-positive

NeuroSense Therapeutics Ltd., a biotechnology company, announced positive initial results from its Phase 2 RoAD clinical trial in collaboration with NeuroKaire. The trial evaluates PrimeC, a treatment for Alzheimers disease, showing improvements in brain-cell connectivity and health with no observed toxicity. NeuroKaires technology generates brain cells from patients blood, allowing for precise analysis using AI-driven analytics. The trials results reinforce PrimeCs potential and guide its development. NeuroSense and NeuroKaire will continue evaluating PrimeCs effects, with top-line data expected after study completion. The findings will be presented at the CNS Summit 2025.

growth-positive

NeuroSense Therapeutics Ltd., a late-clinical stage biotechnology company, announced positive initial results from its Phase 2 RoAD clinical trial for PrimeC, a treatment for Alzheimers disease. The trial, conducted in collaboration with NeuroKaire, demonstrated improvements in neuroplasticity and brain-cell connectivity without treatment-related toxicity. NeuroKaires proprietary technology was used to generate brain cells from patients blood samples, which were then analyzed using AI-driven analytics. These findings support PrimeCs mechanistic rationale and guide its precision development in Alzheimers treatment. The trial is designed to evaluate the safety, efficacy, and biological activity of PrimeC over 12 months.

growth-positive

NeuroSense Therapeutics Ltd., a late-clinical stage biotechnology company, has announced a $500,000 private placement agreement with a single investor. The investment, set at a 40% premium to the market price, aims to provide a short-term financial bridge to support the companys growth and advance its development of treatments for severe neurodegenerative diseases. The funds will be used for general corporate purposes and working capital. The private placement is expected to close on September 8, 2025. This strategic move is part of NeuroSenses ongoing efforts to strengthen its financial position while minimizing shareholder dilution.

growth-positive

NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, is advancing its investigational therapy, PrimeC, for amyotrophic lateral sclerosis (ALS) towards a pivotal Phase 3 trial. The company has regained Nasdaq compliance and strengthened its financial position with a $5 million private placement. NeuroSense plans to submit a new request for a Notice of Compliance in Canada and begin a multinational Phase 3 study of PrimeC in ALS in the second half of 2025. The company is also working on a partnership agreement with a global pharmaceutical partner to advance PrimeCs development and commercialization. Recent data from the Phase 2b PARADIGM study showed promising results, reinforcing PrimeCs potential as a disease-modifying treatment for ALS.

growth-positive

NeuroSense Therapeutics Ltd., a late-stage clinical biotechnology company, provided a business update for the first half of 2025. The company is advancing its investigational therapy, PrimeC, for amyotrophic lateral sclerosis (ALS) and is preparing for a pivotal Phase 3 trial. NeuroSense regained compliance with Nasdaqs stockholders equity requirement after a $5 million private placement in December 2024. The company plans to submit a new request to Health Canada for a Notice of Compliance with conditions (NOC/c) for PrimeC. Additionally, NeuroSense is in discussions for a partnership agreement to develop and commercialize PrimeC. The Phase 2b PARADIGM study showed promising results, reinforcing the potential of PrimeC as a disease-modifying treatment.

growth-positive

NeuroSense Therapeutics Ltd., a late-clinical stage biotechnology company, is set to unveil new insights into its breakthrough science and Canadian regulatory milestones during a live webcast. Hosted by award-winning actor and ALS advocate Aaron Lazar, the event will focus on NeuroSenses investigational therapy, PrimeC, which shows promise in altering the course of ALS. The webcast will also discuss the companys regulatory path in Canada and its binding term sheet with a pharmaceutical partner. The event, scheduled for August 4, 2025, aims to engage the ALS community, media, and biotech investors.

growth-positive

NeuroSense Therapeutics Ltd., a biotechnology company focused on neurodegenerative diseases, is advancing its investigational therapy, PrimeC, for ALS. In a live webcast hosted by actor and ALS advocate Aaron Lazar, NeuroSenses CEO Alon Ben-Noon discussed the promising potential of PrimeC, which has shown efficacy in Phase 2a trials. The webcast also covered NeuroSenses regulatory progress in Canada and a binding term sheet with a pharmaceutical partner. PrimeC, a combination of ciprofloxacin and celecoxib, targets ALS mechanisms and has received Orphan Drug Designation from the FDA and EMA. The event aims to engage the ALS community, media, and investors, highlighting NeuroSenses commitment to addressing unmet medical needs in neurodegenerative diseases.

growth-positive

NeuroSense Therapeutics Ltd. has scaled up production of its lead drug candidate, PrimeC, to a commercial scale. PrimeC is an extended-release oral formulation for treating amyotrophic lateral sclerosis (ALS). The company has enhanced its supply chain and partnered with a global CDMO for manufacturing. NeuroSense is pursuing early market entry in Canada and forecasts potential peak annual revenue of $100-150 million. D. Boral Capital initiated coverage with a Buy rating and a price forecast of $14. The ongoing Phase 2b PARADIGM trial is expected to report results in 2025. NeuroSense is also expanding its platform to target Alzheimers and Parkinsons diseases.

growth-positive

NeuroSense Therapeutics Ltd. has announced a significant milestone in the commercialization of its ALS therapy, PrimeC. The company has scaled up production to commercial levels, backed by a robust manufacturing infrastructure and strategic partnerships with a global CDMO. With validated manufacturing processes and a confirmed 36-month shelf life, NeuroSense is poised to enter the Canadian market, pending regulatory approval. The company aims to leverage the Notice of Compliance with Conditions (NOC/c) pathway for early market entry, projecting a $100-150 million market opportunity in Canada. This development aligns with NeuroSenses long-term growth strategy and positions it for global expansion.

growth-positive

NeuroSense Therapeutics Ltd., a late-stage clinical biotechnology company, is advancing its novel treatment, PrimeC, for ALS. The company is in discussions for a strategic partnership with a global pharmaceutical company, having signed a binding term sheet in December 2024. The partnership is expected to be transformative for NeuroSense. The company is preparing for a Phase 3 clinical trial in the second half of 2025, following positive feedback from the FDA. Additionally, NeuroSense is exploring early access pathways in Canada, aiming to provide patients with earlier access to promising treatments. The developments indicate a positive growth trajectory for the company.

growth-positive

NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, is advancing its novel treatment for ALS, PrimeC, towards a Phase 3 clinical trial. The company is optimistic about a strategic partnership with a global pharmaceutical company, which could significantly enhance its financial position and operational capabilities. NeuroSense is also making progress on the Canadian regulatory pathway, potentially allowing early access to PrimeC for patients with serious conditions. The company has received positive feedback from the FDA and is planning a global Phase 3 trial in the second half of 2025. NeuroSenses financial strategy focuses on maximizing shareholder value while preparing for future growth.

growth-positive

NeuroSense Therapeutics, Ltd., a clinical-stage biotechnology company, announced promising findings from its Phase 2b PARADIGM clinical trial for PrimeC, an investigational therapy for amyotrophic lateral sclerosis (ALS). The trial demonstrated PrimeCs significant impact on miRNA modulation, showing a consistent downregulation of 161 miRNAs in treated patients. This modulation is linked to reduced disease progression and improved survival rates, highlighting PrimeCs potential as a transformative therapy for ALS. The findings underscore the therapys ability to target key pathological processes in ALS, reinforcing its clinical benefits and positioning it as a promising therapeutic candidate.

growth-positive

NeuroSense Therapeutics, Ltd., a clinical-stage biotechnology company, announced promising results from its Phase 2b PARADIGM clinical trial for PrimeC, a therapy for amyotrophic lateral sclerosis (ALS). The findings reveal significant modulation of microRNAs (miRNAs) associated with ALS, suggesting PrimeCs potential to slow disease progression and improve survival rates. The trial demonstrated consistent downregulation of 161 miRNAs in patients treated with PrimeC, highlighting its targeted biological activity. The study, conducted in collaboration with Prof. Noam Shomron of Tel Aviv University, was presented at the 77th Annual American Academy of Neurology Meeting. NeuroSense aims to further explore PrimeCs impact on miRNA maturation and its relevance in other neurodegenerative diseases. PrimeC has been granted Orphan Drug Designation by the FDA and the European Medicines Agency.

growth-positive

NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, reported significant progress in its development of PrimeC, a treatment for amyotrophic lateral sclerosis (ALS). The company completed a Phase 2b study demonstrating that PrimeC slows disease progression and improves survival rates. NeuroSense is in ongoing partnership discussions to advance PrimeC to a Phase 3 study, with plans for initiation in 2025. The study design has been aligned with the FDA, and there are plans for early commercialization in Canada with a potential market opportunity of $100-$150 million in peak annual revenues. A key patent has been granted, extending protection until 2042. Financially, the company reported a decrease in research and development expenses for 2024.

growth-positive

NeuroSense Therapeutics, Ltd., a clinical-stage biotechnology company, announced the presentation of new data from its Phase 2b trial of PrimeC, an investigational therapy for amyotrophic lateral sclerosis (ALS), at the 77th Annual American Academy of Neurology Meeting. The data, presented by members of the companys Scientific Advisory Board, highlighted PrimeCs safety, efficacy, and potential as a disease-modifying therapy for ALS. The presentations also explored the role of microRNA modulation and iron-related pathways in ALS treatment, offering insights into PrimeCs mechanism of action. These findings underscore the potential of PrimeC to redefine ALS treatment and pave the way for a forthcoming Phase 3 trial.

growth-positive

NeuroSense Therapeutics Ltd. is making significant strides towards the commercialization of its ALS treatment, PrimeC, in Canada. The company has been invited by Health Canada for a pre-New Drug Submission meeting, aiming for potential approval by the first half of 2026. PrimeC, which has shown strong clinical efficacy, is expected to generate $100-150 million in annual revenue in Canada. NeuroSense has also secured a binding term sheet with a global pharmaceutical partner to advance PrimeCs development, including funding for its Phase 3 program. This development represents a crucial step in NeuroSenses regulatory strategy and highlights the pharmaceutical industrys interest in innovative neurological therapies.

growth-positive

NeuroSense Therapeutics is making significant strides in ALS treatment with its innovative combination therapy, PrimeC. The therapy, which combines two FDA-approved drugs, has shown remarkable efficacy in reducing disease progression and improving survival rates in a Phase 2b clinical trial. The company is on the verge of a major licensing deal, potentially worth hundreds of millions, as evidenced by similar deals in the industry. NeuroSenses recent partnership term sheet further signals its growth potential in the neurodegenerative disease market. Wall Street maintains a positive outlook on the company, with AGP setting a $7.50 price target.

growth-positive

NeuroSense Therapeutics Ltd., a late-stage clinical biotechnology company, has regained compliance with Nasdaqs stockholders equity requirement, ensuring its continued listing on the Nasdaq Capital Market. This achievement follows the companys successful efforts to improve its financial position by raising $5 million in equity financing in December 2024. NeuroSense is preparing to transition into a pivotal Phase 3 study for its treatment, PrimeC, following promising results from the Phase 2b PARADIGM study. The company will be subject to a mandatory panel monitor for a year to ensure continued compliance. This milestone reflects NeuroSenses strategic direction and progress in addressing the unmet needs of ALS patients.

growth-positive

NeuroSense Therapeutics Ltd., a biotechnology company focused on neurodegenerative diseases, has entered into a binding term sheet with a leading global pharmaceutical company. This agreement aims to advance the development and commercialization of PrimeC, a treatment for amyotrophic lateral sclerosis (ALS). The deal includes a substantial upfront payment, funding for a Phase 3 clinical trial, milestone payments, and double-digit royalties on net sales. The pharmaceutical company will have exclusive rights to market and sell PrimeC in certain territories, while NeuroSense retains rights in others. The agreement is expected to be finalized in Q1 2025. PrimeC has shown positive results in Phase 2 trials, indicating its potential to address unmet medical needs in ALS.

growth-positive

NeuroSense Therapeutics Ltd. has entered into a binding term sheet with a leading global pharmaceutical company to advance the development and commercialization of its ALS treatment drug, PrimeC. The agreement includes a substantial upfront payment, funding for a Phase 3 clinical trial, milestone payments, and a tiered royalty structure on net sales. The pharmaceutical company will have exclusive rights to distribute and market PrimeC in certain key markets, while NeuroSense retains rights in other territories. The definitive agreement is expected to be finalized in Q1 2025. This partnership aims to address the urgent unmet medical need in ALS, a neurodegenerative disease with significant impact.

growth-positive

NeuroSense Therapeutics Ltd., a biotechnology company focused on neurodegenerative diseases, announced significant progress in its clinical trials and financial activities. The company completed an 18-month Phase 2b PARADIGM study, showing promising results for its ALS treatment, PrimeC. Positive feedback from the FDA on the Phase 3 study design positions the company to start this trial in mid-2025. Additionally, NeuroSense secured a $5 million private placement in December 2024, involving a single investor and CEO Alon Ben-Noon. The company is also preparing for early commercialization in Canada, with a potential launch in 2026. These developments indicate a positive growth trajectory for NeuroSense.

growth-positive

NeuroSense Therapeutics Ltd., a biotechnology company focused on developing treatments for neurodegenerative diseases, announced the successful conclusion of a Type C meeting with the FDA regarding their drug PrimeC for ALS treatment. The meeting aimed to discuss the design of a Phase 3 clinical study and the plan for a 505(b)(2) marketing application. The FDA provided positive feedback, marking a significant milestone for NeuroSense. The company plans to submit a final protocol to the FDA in the first half of 2025, with the Phase 3 study expected to commence in mid-2025. This study will evaluate the efficacy and safety of PrimeC in approximately 300 ALS patients. The feedback from the FDA validates NeuroSenses progress and commitment to providing innovative treatments for ALS.

growth-positive

NeuroSense Therapeutics Ltd., a biotechnology company, announced positive results from an 18-month study of PrimeC, a treatment for Amyotrophic Lateral Sclerosis (ALS). The study showed a 33% slower disease progression and a 58% improvement in survival rates for patients who received PrimeC from the start compared to those initially on placebo. The results indicate a significant improvement in ALS Functional Rating Scale-Revised (ALSFRS-R) scores. The findings will be presented at the 2024 International Symposium on ALS/MND. The company plans to update on the outcome of a meeting with the FDA soon. ALS is a severe neurodegenerative disease with a growing patient population, highlighting the potential impact of PrimeC in redefining ALS treatment standards.

growth-positive

NeuroSense Therapeutics Ltd., a biotechnology company focused on developing treatments for neurodegenerative diseases, announced a definitive agreement for a private placement with a single investor and its CEO, Mr. Alon Ben-Noon. The agreement involves the purchase of $5,000,000 worth of ordinary shares and warrants. The private placement, expected to close in December 2024, will provide NeuroSense with funds for general corporate and working capital purposes. The offering is made under an exemption from registration, and the securities cannot be sold in the U.S. without proper registration. NeuroSense aims to address significant unmet medical needs in diseases like ALS, Alzheimers, and Parkinsons through combined therapies targeting multiple pathways.

growth-positive

NeuroSense Therapeutics Ltd., a biotechnology company focused on neurodegenerative diseases, announced a definitive agreement for a private placement with a single investor and its CEO, Alon Ben-Noon. The agreement involves the purchase of $5,000,000 in ordinary shares and warrants, with the shares priced at $1.25 each, 25% above the closing price on November 29, 2024. The warrants, valid for five years, allow the purchase of additional shares at the same price. The funds will be used for general corporate and working capital purposes. The private placement is expected to close in December 2024, relying on an exemption from registration under the Securities Act.

growth-positive

NeuroSense Therapeutics Ltd., a biotechnology company focused on developing treatments for neurodegenerative diseases, will participate in the 2024 International Symposium on ALS/MND in Montreal. The company will present findings from its Phase 2b PARADIGM trial of PrimeC, a potential treatment for ALS. Notable presentations will include insights from Prof. Merit Cudkowicz and Dr. Cristian Lunetta on clinical outcomes and biomarker analysis, respectively. The event underscores NeuroSenses leadership in ALS research and its commitment to innovative treatment strategies. The symposium is a key global forum for ALS research, highlighting the companys dedication to addressing ALS patient needs.

growth-positive

NeuroSense Therapeutics Ltd., a biotechnology company focused on neurodegenerative diseases, announced its participation in the 2024 International Symposium on ALS/MND in Montreal, Canada. The company will present findings from its Phase 2b PARADIGM trial of PrimeC, a potential treatment for ALS. Key presentations will be made by Prof. Merit Cudkowicz and Dr. Cristian Lunetta, highlighting clinical outcomes and biomarker analysis. The trial showed promising results, with PrimeC demonstrating a significant slowing of ALS progression compared to placebo. NeuroSenses involvement underscores its commitment to advancing ALS research and addressing unmet patient needs. The symposium serves as a global forum for discussing advancements in ALS research.

growth-positive

NeuroSense Therapeutics Ltd. is preparing for an FDA Type C meeting on November 6 to discuss the design of its Phase 3 clinical trial for PrimeC, a potential treatment for ALS. The meeting is crucial for finalizing the trial design and aligning the companys regulatory strategy with FDA requirements. NeuroSense also plans to submit a regulatory dossier to Health Canada by Q2 2025, with a decision expected by Q1 2026. The potential market opportunity for PrimeC in Canada is estimated to be $100 million to $150 million annually. The company is in advanced discussions with several large pharmaceutical companies for a strategic partnership to develop and commercialize PrimeC.

growth-positive

NeuroSense Therapeutics Ltd., a biotechnology company focused on treatments for neurodegenerative diseases, is preparing for a Type C meeting with the FDA on November 6, 2024. The meeting will discuss the design of a Phase 3 clinical trial for PrimeC, a potential treatment for Amyotrophic Lateral Sclerosis (ALS). NeuroSense aims to align its regulatory strategy with FDA requirements and plans to submit a New Drug Application (NDA) in the future. In parallel, the company plans to submit its regulatory dossier to Health Canada in Q2 2025, with a decision expected by Q1 2026. PrimeC has shown promising results in clinical trials, significantly reducing disease progression and improving survival rates. The potential market opportunity for PrimeC in Canada is estimated at $100 million to $150 million annually.

growth-positive

NeuroSense Therapeutics Ltd., a biotechnology company, announced transformative findings from its PARADIGM clinical trial of PrimeC, a novel treatment for ALS (Amyotrophic Lateral Sclerosis). The trial demonstrated PrimeCs significant impact on the regulation of microRNAs (miRNAs), which are crucial in ALS progression. By restoring balance to these genetic regulators, PrimeC offers a new method of combating ALS, potentially slowing disease progression and improving patient outcomes. The trial results showed a clear differentiation from placebo, highlighting PrimeCs potential as a disease-modifying treatment. This breakthrough in understanding ALSs molecular drivers marks a significant advancement in developing effective treatments for this devastating disease.

growth-positive

NeuroSense Therapeutics Ltd., a biotechnology company focused on neurodegenerative diseases, plans to file for early commercialization approval for its drug PrimeC in Canada under Health Canadas Notice of Compliance with Conditions policy. This follows promising results from the Phase 2b ALS PARADIGM clinical trial, which showed significant reduction in disease progression and improved survival rates. The company estimates a potential market opportunity in Canada with peak annual revenue of $100M to $150M, driven by the prevalence of ALS and unmet demand for effective treatments. NeuroSense aims to expand approval efforts to additional global markets, marking a significant milestone in addressing ALS treatment needs and driving sustainable growth.

growth-positive

NeuroSense Therapeutics Ltd., a biotechnology company, has initiated the regulatory process to seek early commercialization approval for its drug PrimeC in Canada. This follows positive results from its Phase 2b ALS PARADIGM clinical trial, which showed a significant reduction in ALS disease progression and improved survival rates. The company plans to seek approval in additional countries, aiming to expedite access to this promising therapy for ALS patients. PrimeC, an extended-release oral formulation, targets key mechanisms of ALS and has shown efficacy beyond the standard ALS treatment. NeuroSense is committed to advancing regulatory approvals and addressing unmet needs in ALS treatment.

growth-positive

NeuroSense Therapeutics Ltd., a biotechnology company focused on neurodegenerative diseases, announced the acceptance of two abstracts on its lead drug candidate, PrimeC, for ALS treatment. These will be presented at the 2024 NEALS Consortium Meeting. The abstracts highlight data from the Phase 2b PARADIGM study, showing PrimeCs potential in reducing ALS disease progression by 36% and improving survival rates by 43% compared to placebo. The study involved 68 participants across Canada, Italy, and Israel, with most opting to continue PrimeC treatment post-trial. PrimeC, a combination of ciprofloxacin and celecoxib, targets key ALS mechanisms. NeuroSenses commitment to ALS research and innovative treatments is underscored by these findings.

growth-positive

NeuroSense Therapeutics Ltd., a biotechnology company focused on neurodegenerative diseases, announced the acceptance of two abstracts on their lead drug candidate, PrimeC, for ALS treatment. These abstracts will be presented at the 2024 NEALS Consortium Meeting. The data from the Phase 2b PARADIGM study showed PrimeC significantly reduced ALS disease progression and improved survival rates compared to placebo. PrimeC, an oral formulation combining ciprofloxacin and celecoxib, targets key ALS mechanisms. The trials success underscores NeuroSenses commitment to ALS research and innovative treatments. The company aims to address unmet medical needs in neurodegenerative diseases through combined therapies targeting multiple pathways.

growth-positive

NeuroSense Therapeutics Ltd. announced that it has regained compliance with Nasdaqs minimum bid price requirement, maintaining a minimum closing bid price of $1.00 or more for at least 10 consecutive business days as of September 20, 2024. This milestone allows the company to continue its listing on Nasdaq. CEO Alon Ben-Noon expressed satisfaction with this achievement and highlighted the companys plans to initiate a Phase 3 trial for its drug PrimeC in the US. NeuroSense focuses on developing treatments for severe neurodegenerative diseases such as ALS, Alzheimers, and Parkinsons. The company is also in discussions with potential partners to advance its clinical programs.

growth-positive

NeuroSense Therapeutics Ltd., a biotechnology company focused on neurodegenerative diseases, announced the issuance of a pivotal patent by the USPTO for its leading drug candidate, PrimeC. The patent, which extends protection until 2042, covers the combination and formulation of ciprofloxacin and celecoxib, designed to treat Amyotrophic Lateral Sclerosis (ALS). Recent clinical trials demonstrated significant efficacy in slowing ALS progression and improving survival rates. This patent strengthens NeuroSenses intellectual property and supports its innovative approach to ALS treatment, potentially enhancing its market position and growth prospects.

growth-positive

NeuroSense Therapeutics Ltd. announced the issuance of a pivotal patent by the USPTO for its lead drug candidate, PrimeC, which is designed to treat Amyotrophic Lateral Sclerosis (ALS). The patent extends PrimeCs protection until 2042, adding four additional years. PrimeC, composed of ciprofloxacin and celecoxib, has shown promising clinical results, including a 36% reduction in disease progression and a 43% improvement in survival rates compared to placebo. The patent grant follows successful Phase 2b clinical trial results, further solidifying PrimeCs potential as a breakthrough therapy for ALS.

growth-negative

NeuroSense Therapeutics Ltd., a late-clinical stage biotechnology company, received a notification from Nasdaq indicating non-compliance with the minimum bid price requirement of $1.00 per share for 30 consecutive trading days. The company has until February 24, 2025, to regain compliance. If it fails to do so, it may be granted an additional 180 days to meet the requirement, provided it meets other listing standards. The notification does not immediately affect the companys Nasdaq listing or trading of its shares. NeuroSense continues to focus on developing treatments for neurodegenerative diseases and will monitor its stock price to regain compliance.

growth-negative

NeuroSense Therapeutics Ltd., a biotechnology company focused on developing treatments for neurodegenerative diseases, has received a notification from Nasdaq indicating non-compliance with the minimum bid price requirement. The companys stock has been below $1.00 for 30 consecutive trading days. NeuroSense has until February 24, 2025, to regain compliance by maintaining a closing bid price of at least $1.00 per share for 10 consecutive business days. The notification does not immediately affect the companys Nasdaq listing or trading. If compliance is not met, the company may receive an additional 180 days to rectify the issue. Business operations remain unaffected by this notice.

growth-positive

NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) is in advanced discussions with several multi-billion-dollar pharmaceutical companies for a strategic partnership to develop and commercialize its lead drug candidate, PrimeC, for Amyotrophic Lateral Sclerosis (ALS). These talks could result in substantial financial benefits, including upfront, milestone, and royalty payments. NeuroSense expects to receive terms by Q4 2024, although no definitive agreement is assured. Recent 12-month data from the PARADIGM Phase 2b study showed PrimeCs effectiveness in improving ALS patient outcomes, including better survival rates and functionality compared to placebo. The companys stock closed at $0.74 on Tuesday.

Growth-Positive

NeuroSense Therapeutics Ltd., a late-clinical stage biotechnology company, has entered into a definitive agreement with certain investors for a private placement of $600,000 of ordinary shares and warrants. The investors include senior management of NeuroSense, the CEO, the CFO, the CMO, and members of the CEOs family, as well as previously existing shareholders. The proceeds from the private placement will be used for general corporate and working capital purposes. The private placement is expected to close during the week of August 12, 2014.

growth-positive

NeuroSense Therapeutics Ltd. has announced positive 12-month iron biomarker data from its Phase IIb study (PARADIGM), which evaluated the safety and efficacy of PrimeC in people living with Amyotrophic Lateral Sclerosis (ALS). The data aligns with the companys recent announcements of improved survival by 43% and slowed disease progression by 36%. The results demonstrate the target engagement of PrimeC in iron regulation, which is linked to disease mitigation and improved survival. The company is currently compiling additional data to share with the FDA and is in advanced discussions with potential development partners to explore marketing opportunities.

Growth-Positive

NeuroSense Therapeutics Ltd. has announced positive results from its 12-month PARADIGM Phase 2b study of PrimeC in ALS patients. The study showed a 57% difference in favor of PrimeC over placebo after 12 months of treatment. NeuroSense plans to submit these results to regulatory agencies, including the FDA, to discuss PrimeCs path forward. The companys CEO, Alon Ben-Noon, stated that the results are unprecedented in a 12-month ALS placebo-controlled clinical study and they are eager to present them to the FDA and other regulatory agencies. The company also plans to share the outcomes with potential partners currently conducting due diligence.

growth-positive

NeuroSense Therapeutics Ltd. has reported significant results from the 12-month data analysis of the PARADIGM Phase 2b study evaluating PrimeC in people living with Amyotrophic Lateral Sclerosis (ALS). The data showed a significant improvement in the rate of decline of ALS Functional Rating Scale-Revised (ALSFRS-R) scores and survival rates for subjects who received PrimeC from the start of the trial compared to those who started on placebo. The company is now planning for a Phase 3 clinical study in the U.S. and Europe.

growth-positive

NeuroSense Therapeutics Ltd. has announced positive 6-month clinical outcomes from its phase 2b (PARADIGM) clinical trial. The company is developing treatments for severe neurodegenerative diseases and the trial demonstrated a significant slowing of disease progression in high-risk ALS patients treated with PrimeC. The company expects additional biomarker and 12-month clinical in the near term. It has also started preparations for a Phase 3 clinical trial in the US. The company also provided its Q1 2024 financial results, with research and development expenses for the three months ended March 31, 2024 and 2023 at $1.88 and $1.85 million, respectively.

growth-negative

NeuroSense Therapeutics Ltd., a company developing treatments for severe neurodegenerative diseases, has received a notice of delisting from Nasdaq. The companys securities have not regained compliance with the minimum $2,500,000 stockholders equity requirement for continued listing on The Nasdaq Capital Market. NeuroSense intends to request a hearing before a Nasdaq Hearings Panel to present its plan for regaining and sustaining compliance with the Equity Requirement for continued listing.

growth-positive

NeuroSense Therapeutics Ltd. announces that its Vice President of R&D, Dr. Shiran Zimri, will present at the ALS Drug Development Summit in Boston on May 22, 2024. She will provide an update on the companys latest findings from its phase 2b clinical trial (PARADIGM) and discuss the potentials of combination therapy in ALS. The company recently announced additional results of its PARADIGM trial that showed a significant slowing of disease progression in high-risk ALS patients treated with PrimeC.

growth-positive

NeuroSense Therapeutics has partnered with PhaseV, a pioneer in causal machine learning for clinical trial analysis and optimization, for the planned Phase 3 trial of PrimeC, a treatment for amyotrophic lateral sclerosis (ALS). PhaseV conducted an independent analysis of NeuroSenses Phase 2b study and predicts a high probability of success in multiple subgroups for the planned Phase 3 trial. The insights gained from this collaboration will significantly inform study design, patient enrollment and ensure cost-effectiveness. NeuroSense recently reported positive efficacy and safety data from its Phase 2b trial and is planning on embarking on a Phase 3 pivotal trial in the next few months.

growth-positive

NeuroSense Therapeutics Ltd. has announced new analyses from its Phase 2b PARADIGM clinical trial, demonstrating a significant slowing of disease progression in high-risk ALS patients treated with PrimeC. The results show a 43% slowing of disease progression compared to a placebo after 6 months of treatment. The company believes these results are some of the most compelling seen to-date in an advanced, double-blind clinical trial in ALS. The company plans to use these subgroup analyses to inform the design of the upcoming pivotal trial.

Growth-Positive

NeuroSense Therapeutics Ltd. has provided a business update, highlighting collaborations with Genetika+ and Lonza to advance its Phase 2 Alzheimers disease trial and identify exosome-based biomarkers respectively. The company also announced positive results from its PARADIGM Study, which showed positive trends of key biomarker outcome of neurofilament light chain levels. NeuroSenses CEO, Alon Ben-Noon, stated that the first few months of 2024 have been productive for the company, and they anticipate further collaborations and the scheduling of an end of Phase 2 study with FDA.

growth-positive

NeuroSense Therapeutics Ltd. has announced a collaboration with Genetika+ in Alzheimers Disease (AD) drug development. The collaboration will commence in NeuroSenses ongoing Phase 2 AD clinical trial and will leverage Genetika+s technology that derives frontal cortex neurons from individual patients blood to quantify drug-induced neuronal plasticity in vitro. The technology will be used to correlate clinical response with cellular effects, supporting drug development and potentially commercialization. The collaboration aims to address key challenges in the development of drugs for AD, promoting disease and drug mechanistic understanding, increasing the likelihood of success of AD drug development, and enabling the realization of precision medicine approaches.

growth-positive

NeuroSense Therapeutics Ltd. has presented data from its PARADIGM Phase 2b study of PrimeC, a novel treatment for severe neurodegenerative diseases, at the American Academy of Neurology Annual Meeting. The study showed positive clinical outcomes and a trend towards impact on Neurofilament levels. The study demonstrated that PrimeC met safety and tolerability measures and showed a significant slowing of disease progression. The company is focused on discovering and developing treatments for neurodegenerative diseases such as ALS, Alzheimers disease, and Parkinsons disease.

growth-positive

NeuroSense Therapeutics Ltd. has announced that data from the PARADIGM Phase 2 study of PrimeC will be presented at the American Academy of Neurology Annual Meeting. The presentation will be made by Merit Cudkowicz, Chair of Neurology at Massachusetts General Hospital, and Julieanne Dorn Professor of Neurology at Harvard Medical School. NeuroSense is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases, including ALS, Alzheimers disease, and Parkinsons disease.

growth-positive

NeuroSense Therapeutics Ltd. has entered into a securities purchase agreement with a single health-care focused institutional investor. The agreement involves the purchase and sale of 2,980,000 ordinary shares in a registered direct offering and ordinary warrants to purchase up to 2,980,000 ordinary shares in a concurrent private placement. The combined purchase price is $1.50 per ordinary share. The gross proceeds from the offering are expected to be approximately $4.5 million, excluding any proceeds that may be received upon the exercise of the warrants. The company intends to use the net proceeds for working capital and general corporate purposes.

growth-positive

NeuroSense Therapeutics and Lonza have announced a collaboration to evaluate biological changes in people with neurodegenerative diseases, including ALS. The partnership will provide NeuroSense with access to Lonzas expertise in extracellular vesicles. NeuroSense will leverage its experience in biomarker utilization in neurodegenerative diseases, while Lonza will develop, optimize, and qualify a method for measuring biomarkers from Neuron-Derived Exosomes (NDEs). These will be integrated into the development of NeuroSenses lead product candidate for ALS, PrimeC. The collaboration is expected to advance early diagnosis and treatment in the neurodegeneration field.

growth-positive

NeuroSense Therapeutics Ltd. has reported its financial results for the year ended December 31, 2023, and provided a business update. The companys Phase 2b PARADIGM ALS trial showed a significant slowing of disease progression in patients treated with PrimeC compared to a placebo. The companys research and development expenses increased by 18% due to an increase in the number of employees and subcontractor and consulting expenses. As of December 31, 2023, NeuroSense had cash of approximately $2.6 million.

growth-positive

NeuroSense Therapeutics Ltd. has reported positive data from its Phase 2b PARADIGM trial of its lead drug candidate, PrimeC, for the treatment of amyotrophic lateral sclerosis (ALS). The trials secondary clinical efficacy outcome measure endpoints included Quality of Life and Survival. PrimeC displayed a clinically meaningful effect on various aspects of patients quality of life, including mental and physical health. It also reduced the risk of ALS disease complications or death by up to 53%. The company had previously reported positive top-line results from the PARADIGM trial in December 2023.

growth-positive

NeuroSense Therapeutics Ltd. has regained compliance with the Nasdaqs minimum bid price requirement, following a period of maintaining a minimum closing bid price of $1.00 or more for at least 10 consecutive business days. The companys CEO, Alon Ben-Noon, stated that this is an important event as they continue to focus on the advancement of PrimeC, a treatment for neurodegenerative diseases. The company recently announced positive top-line results from the Phase 2b PARADIGM trial and is looking forward to reporting results from their collaboration with Biogen.

growth-positive

NeuroSense Therapeutics Ltd is making strides in the treatment of Amyotrophic lateral sclerosis (ALS) with its lead therapeutic candidate, PrimeC. The drug, which combines two FDA-approved drugs, showed a significant decline in disease progression and slowing of the loss of respiratory function in a phase 2b ALS trial. The company is now preparing for a phase 3 trial and is in talks with several big pharma companies to explore potential strategic partnerships. NeuroSense is also collaborating with Biogen Inc. to evaluate the impact PrimeC has on neurofilament levels in trial participants.

growth-positive

NeuroSense Therapeutics Ltd. has shared a review of its clinical achievements in 2023 and provided a roadmap for anticipated catalysts in 2024. The companys Phase 2b PARADIGM trial of PrimeC showed a significant slowing of disease progression in ALS patients. NeuroSense is also expecting to report results from a strategic collaboration with Biogen in January 2024, evaluating the impact of PrimeC on neurofilament levels in participants enrolled in PARADIGM. The company has entered into advanced discussions with biotech VCs and several big pharma companies to explore potential strategic partnerships and business opportunities.

growth-negative

NeuroSense Therapeutics Ltd., a company developing treatments for severe neurodegenerative diseases, has received a notification from the Nasdaq Stock Market LLC advising that it no longer satisfies the minimum $2.5 million stockholders equity requirement for continued listing on Nasdaq. The company has until February 5, 2024, to submit a plan to regain compliance. The notification does not affect the companys ongoing operations or its commitment to advance its lead drug candidate, PrimeC, towards the market.

growth-positive

NeuroSense Therapeutics Ltd. has reported positive efficacy data from its Phase 2b trial (PARADIGM) with its lead drug candidate for amyotrophic lateral sclerosis (ALS), PrimeC. The trial showed a statistically significant slowing of disease progression in patients treated with PrimeC compared to a placebo. The company expects to report results from a strategic collaboration with Biogen in January 2024, evaluating the impact of PrimeC on neurofilament levels in participants enrolled in PARADIGM. NeuroSense also plans to hold an End of Phase 2 meeting with the FDA and a Scientific Advice meeting with the European Medicines Agency (EMA) to discuss these results and to determine the best path forward for PrimeCs development in the first half of 2024.

growth-negative

NeuroSense Therapeutics is facing a potential cash burn issue, with its cash reserves only covering about eight months of operations as of September 2023. The companys cash burn has increased by 13% over the past year, indicating increased investment in growth. However, this is reducing the companys cash runway. If NeuroSense needs to raise more cash, it may have to issue more shares, leading to dilution for current shareholders. The companys cash burn of $7.4m is about 37% of its $20m market capitalisation.

growth-positive

NeuroSense Therapeutics Ltd. has reported positive results from its Phase 2b clinical trial of PrimeC, a drug candidate for the treatment of amyotrophic lateral sclerosis (ALS). The trial met its primary safety and tolerability endpoints and showed a slowing of disease progression in patients treated with PrimeC. The company expects to report additional data in the first half of 2024. NeuroSense is also collaborating with Biogen to evaluate the impact of PrimeC on neurofilament levels in participants, with results expected in January 2024. The company plans to advance discussions with the FDA and strategic partners to determine the best path forward for PrimeC.

Growth-Positive

NeuroSense Therapeutics Ltd. is set to report new data from the randomized, placebo-controlled, double-blind segment of its ongoing Phase 2b amyotrophic lateral sclerosis (ALS) trial of its lead drug candidate PrimeC. The data will include primary safety and tolerability endpoints as well as secondary clinical efficacy outcome measures. PrimeC is a novel extended-release oral formulation composed of a unique fixed-dose combination of two FDA-approved drugs: ciprofloxacin and celecoxib. It is designed to target several key mechanisms of ALS that contribute to motor neuron degeneration, inflammation, iron accumulation and impaired RNA regulation to potentially inhibit the progression of ALS.

growth-positive

NeuroSense Therapeutics Ltd. has reported its financial results for the nine months ended September 30, 2023, and provided a business update. The company is developing treatments for severe neurodegenerative diseases and is looking forward to reporting topline clinical results from their Phase 2b ALS study in early December. NeuroSense has also completed the 6-month double-blind segment of PARADIGM, a placebo-controlled, multi-center Phase 2b clinical trial using a unique upgraded formulation of PrimeC. The company has a cash runway extending towards the end of Q2 2024 and is well positioned to advance discussions with potential strategic partners.

growth-positive

NeuroSense Therapeutics Ltd. has successfully concluded a Type D meeting with the U.S. Food and Drug Administration (FDA) for PrimeC, a treatment for amyotrophic lateral sclerosis (ALS). The meeting was to discuss PrimeCs chemistry, manufacturing, and controls (CMC) development plans ahead of a planned Phase 3 pivotal study and potential marketing approval. The FDA agreed with NeuroSenses proposed CMC development plan. PrimeC has already been granted Orphan Drug Designation by the FDA and the European Medicines Agency (EMA).

Growth-Positive

NeuroSense Therapeutics Ltd., a company developing treatments for severe neurodegenerative diseases, announced that the last patient has completed the double-blind segment of its Phase 2b PARADIGM trial for ALS. Top-line results are expected in December 2023. The company will present its latest findings at three upcoming conferences: Neuroscience 2023, ALS ONEs 6th Annual ALS Research Symposium, and the 34th International Symposium on ALS/MND. The presentations will focus on the companys innovative approach of using biomarkers as a primary efficacy endpoint in the PARADIGM study.

growth-positive

NeuroSense Therapeutics has completed dosing of the last patient in the double-blind segment of its Phase 2b amyotrophic lateral sclerosis (ALS) trial of PrimeC. Sixty-nine people living with ALS in Canada, Italy, and Israel were enrolled in the trial. The company expects to release clinical efficacy results from the trial in December 2023. Additionally, in the first quarter of 2024, the company expects to report results from a strategic collaboration with Biogen that is evaluating the impact of PrimeC on patients enrolled in the trial.

growth-positive

NeuroSense Therapeutics Ltd. announced that its Chief Medical Officer, Dr. Ferenc Tracik, will participate in the 29th annual BIO-Europe Fall partnering conference in Munich, Germany. Dr. Tracik will meet with potential strategic partners and collaborators regarding NeuroSenses advancing development pipeline. The companys lead combination drug, PrimeC, is in a global Phase 2b study for amyotrophic lateral sclerosis (ALS). Other programs include the treatment of Alzheimers disease, heading into Phase 2, and Parkinsons disease, now in the pre-clinical phase.

growth-positive

NeuroSense Therapeutics Ltd. has announced the results of a non-sponsored in vitro study of PrimeC in amyotrophic lateral sclerosis (ALS) conducted by Dr. Justin Ichida at the University of Southern Californias Stem Cell Ichida Lab. The study used induced pluripotent stem cells (iPSCs) derived from blood samples of people living with ALS. PrimeC showed a significant beneficial effect, demonstrating the synergistic effect of PrimeC and supporting the rationale of combining the two active components into NeuroSenses proprietary formulation. NeuroSense expects clinical topline results from its Phase 2b study of PrimeC in the treatment of ALS in the fourth quarter of 2023.

Growth-Positive

EmergingGrowth.com, a leading independent small cap media portal, has announced the schedule for the 63rd Emerging Growth Conference on October 4th and 5th, 2023. The conference aims to identify companies in various growth sectors that have strong management teams, innovative products and services, a focused strategy, and the potential for long-term growth. Several companies, including AGBA Group Holding Limited, Loop Industries, Inc., and CoTec Holdings Corp., among others, are set to present at the conference.

growth-positive

NeuroSense Therapeutics Ltd., a company developing treatments for severe neurodegenerative diseases, has announced the termination of its at-the-market equity offering program. The termination will take effect at the close of business on October 4th, 2023. The company has completed enrollment in its Phase 2b ALS trial and expects to enroll its first patient in a new Phase 2 Alzheimers disease study in the coming weeks. The company is fully funded into the second quarter of 2024.

growth-positive

NeuroSense Therapeutics Ltd. has announced the opening of an EU Office and has been granted Small and Medium-Sized Enterprise (SME) status by the European Medicines Agency (EMA). The SME status offers benefits such as regulatory guidance and financial benefits. The company has completed enrollment in its Phase 2b multinational clinical study of PrimeC for the treatment of ALS, with results expected at the end of 2023. The company plans to commence a global pivotal Phase 3 study of PrimeC in ALS in 2024.

growth-positive

NeuroSense Therapeutics Ltd. has been granted a key patent by the European, Japan, and Israel Patent Offices. The patent relates to NeuroSenses unique fixed-dose combination of ciprofloxacin and celecoxib, the active ingredients in PrimeC, the companys lead drug candidate for treating Amyotrophic Lateral Sclerosis (ALS). Corresponding patents have been issued in the U.S., Canada, and Australia and are valid through 2038. Additional patent applications for the novel formulation of PrimeC and methods for the treatment of other neurodegenerative diseases are pending.

Growth-Positive

NeuroSense Therapeutics Ltd. announced its participation in upcoming ALS conferences where it will present its PARADIGM Phase 2b ALS study. The company has completed patient enrollment for its combination drug therapy, PrimeC, and expects to report results in Q4 2023. The clinical trial aims to evaluate ALS biomarkers, clinical efficacy, and improvement in quality of life. Over 96% of participants who completed the trial chose to continue in the study and be treated with PrimeC through a 12-month open-label extension.

Growth-Positive

NeuroSense Therapeutics Ltd., a company developing treatments for severe neurodegenerative diseases, will host an investor webinar conference on Tuesday, September 12, 2023. The presentation will focus on NeuroSenses scientific advances, its Phase 2b amyotrophic lateral sclerosis (ALS) clinical trial design, endpoints, and progress, Alzheimer Disease (AD) Phase 2 study design, endpoints, and progress, as well as upcoming catalysts. The company is in a strong financial position following a successful financing in June 2023.

growth-positive

NeuroSense Therapeutics Ltd. has announced the completion of patient enrollment for its Phase 2b ALS study, with topline results expected in Q4 2023. The company also raised $4.5 million in capital in Q2 2023, ensuring funding until Q2 2024. A strategic scientific agreement with Biogen was announced in May 2023 to evaluate the impact of PrimeC on neurofilament levels in the plasma of participants in NeuroSenses Phase 2b ALS PARADIGM trial. The company is also preparing to commence a Phase 2 double-blind proof-of-concept clinical study for Alzheimers Disease.

growth-positive

NeuroSense Therapeutics Ltd., a company developing treatments for severe neurodegenerative diseases, has announced that it will host an investor conference at its U.S. office in Cambridge, Massachusetts on July 24, 2023. The companys executive team will present updates on NeuroSenses scientific advances, its Phase 2b ALS clinical trial design and endpoint analysis, upcoming catalysts, the companys strategy, and potential future partnerships. The Phase 2b clinical trial has completed enrollment and topline results are expected in Q4 2023.

growth-positive

NeuroSense Therapeutics Ltd., a company developing treatments for severe neurodegenerative diseases, announced its participation in two upcoming conferences - the European Network to Cure ALS (ENCALS) and the EverythingALS Digital Biomarkers Summit. The company aims to create new partnerships at ENCALS and strengthen existing connections with the European ALS scientific community. At the EverythingALS Summit, NeuroSense will share insights and commit to advancing biomarker and clinical trial end point development for ALS.

growth-positive

NeuroSense Therapeutics has entered into a securities purchase agreement with a single health-care focused institutional investor for the purchase and sale of 3,000,000 ordinary shares in a registered direct offering and ordinary warrants to purchase up to 3,000,000 ordinary shares in a concurrent private placement. The offering is expected to raise approximately $4.5 million, which will be used to advance the clinical development of its lead product candidate and for other research and development purposes. The closing of the offering is expected to occur on or about June 26, 2023.

growth-positive

NeuroSense Therapeutics Ltd. has announced its Q1 2023 financial results and provided a business update. The company has completed patient enrollment in its Phase 2b ALS trial and is optimistic about the results. NeuroSense is also preparing for a Phase 2 Alzheimers Disease trial and has reported positive results from a Parkinsons Disease biomarker study. The company has established collaborations with Massachusetts General Hospitals NeuroEpigenetics Lab and QuantalX. Research and development expenses increased to $2.09 million, while general and administrative expenses decreased to $1.54 million. As of March 31, 2023, NeuroSense had cash and short-term deposits of $4.41 million.

growth-positive

NeuroSense Therapeutics Ltd. has announced the completion of enrollment in its Phase 2b clinical trial of PrimeC, a treatment for amyotrophic lateral sclerosis (ALS). The trial, named PARADIGM, is multinational, randomized, double-blind, and placebo-controlled. Participants are dosed for 6 months after being randomized to receive PrimeC or a placebo, followed by a 12-month open label extension phase where they receive PrimeC. The study enrolled 69 participants living with ALS in Israel, Italy, and Canada. Topline results are expected in Q4 2023.

growth-positive

NeuroSense Therapeutics has announced positive preliminary results from a biomarker study evaluating the potential of its combination platform therapy for the treatment of Parkinsons disease (PD). The study compared blood samples from healthy individuals to those from PD patients and found a statistically significant decrease in levels of the biomarker AGO2 in newly diagnosed PD patients. NeuroSenses combination therapy has shown potential in increasing AGO2 levels in ALS patients, indicating therapeutic potential in PD. The company is now looking to co-develop its PD asset with collaborators focused on Parkinsons. Parkinsons disease is the second most common neurodegenerative disorder, and the global PD treatment market is projected to reach $10.4 billion by 2031.

growth-positive

NeuroSense Therapeutics Ltd. has provided an update on its clinical and operational developments for Q1 2023. The companys Phase 2b ALS PARADIGM Trial has achieved 80% patient enrollment, with results expected in H2 2023. A Phase 2 Alzheimers Disease trial is under preparation, with the first patient expected to be enrolled in Q3 2023. NeuroSense will collaborate with QuantalX for this trial. A Parkinsons Disease biomarker study has been completed, with results expected in May. The company has also entered a collaboration agreement with Massachusetts General Hospitals NeuroEpigenetics Lab.

growth-positive

NeuroSense Therapeutics has signed a collaboration agreement with Dr. Ghazaleh Sadri-Vakili and Massachusetts General Hospitals NeuroEpigenetics Lab to explore the neurotherapeutic effects of its lead combination drug, PrimeC, in treating ALS. The collaboration will involve in vitro studies using a novel model generated from post-mortem ALS brain tissue. The objective is to understand PrimeCs mechanism of action in attenuating ALS-related pathology. Preliminary results from the collaboration will be presented at the AD/PD 2023 Advances in Science & Therapy Conference. PrimeC is currently being evaluated in a Phase 2b ALS trial called PARADIGM. NeuroSense is a clinical-stage biotechnology company focused on developing treatments for neurodegenerative diseases.

growth-positive

NeuroSense Therapeutics Ltd. is developing treatments for severe neurodegenerative diseases. The companys Vice President of R&D, Dr. Shiran Zimri, will present two presentations at the AD/PD™ 2023 Advances in Science & Therapy Conference. The companys lead drug candidate, PrimeC, is currently being evaluated for the treatment of ALS in a Phase 2b study, with results expected in H2 2023. A Phase 2 double-blind proof-of-concept AD study is expected to commence in H1 2023. PrimeC has demonstrated efficacy in pre-clinical models of ALS and was shown to be safe and tolerable in a Phase 2a clinical trial.

growth-positive

NeuroSense Therapeutics Ltd. has released its annual report on Form 20-F, which includes audited consolidated financial statements for the year ended December 31, 2022. The company has made progress in advancing its lead combination drug candidate PrimeC for the treatment of amyotrophic lateral sclerosis (ALS) in the Phase 2b PARADIGM trial. NeuroSense also obtained positive results in a biomarker study in Alzheimers disease and plans to commence a Phase 2 trial for this indication during the first half of this year. The company has partnered with QuantalX to improve early detection and treatment of neurodegenerative diseases.

Growth-Positive

NeuroSense Therapeutics Ltd., a company developing treatments for severe neurodegenerative diseases, announced its participation in the 17th annual BIO-Europe Spring partnering conference in Basel, Switzerland. The companys Chief Medical Officer Dr. Ferenc Tracik and VP of Business Development Nedira Salzman-Frenkel will meet with potential strategic partners and collaborators regarding NeuroSenses advancing development pipeline. The companys lead combination drug PrimeC is in a global Phase 2b study for amyotrophic lateral sclerosis (ALS) with topline results expected in H2 2023. Other programs include the treatment of Alzheimers disease, headed into Phase 2 in H1 2023, and Parkinsons disease now in the pre-clinical phase with biomarker data expected in H1 2023.

growth-positive

NeuroSense Therapeutics Ltd. will be participating in Renmark Financial Communications Inc.s live Virtual Non-Deal Roadshow Series to discuss its latest investor presentation. The company is focused on discovering and developing treatments for neurodegenerative diseases. The roadshow will cover topics related to the investor presentation and include a live Q&A session. NeuroSense Therapeutics invites stakeholders, investors, and other followers to register and attend the events. The presentations will be led by the CEO and VP of Business Development. Registration for the live events may be limited, but access to the replay will be available on the companys investor website.

growth-positive

NeuroSense Therapeutics has received regulatory approval from Germanys Federal Institute for Drugs and Medical Devices to enroll patients in its Phase 2b study of its lead combination drug candidate PrimeC for the treatment of amyotrophic lateral sclerosis (ALS). The company expects to enroll the first study participant in Germany in the next few weeks and plans to complete enrollment and report data in the second half of this year. PrimeC is an extended-release oral formulation composed of a combination of two FDA-approved drugs and is designed to target key mechanisms of ALS. NeuroSense completed a Phase 2a study that showed positive results in reducing functional and respiratory deterioration in ALS patients. ALS is an incurable neurodegenerative disease that causes paralysis and death within 2-5 years from diagnosis. NeuroSense Therapeutics is a clinical-stage biotechnology company focused on developing treatments for neurodegenerative diseases.

growth-positive

NeuroSense Therapeutics has received regulatory approval from Health Canada to commence enrollment for its Phase 2b PARADIGM study of its combination therapy PrimeC for the treatment of amyotrophic lateral sclerosis (ALS). The study is expected to have topline results in the second half of 2023. The U.S. FDA requested additional non-clinical data from NeuroSense to support the duration of the trial, and as a result, NeuroSense will withdraw its study protocol from the Investigational New Drug application (IND). NeuroSense is planning a meeting with the FDA to align its clinical and regulatory strategy for a potential Phase 3 trial. The companys CEO, Alon Ben-Noon, expressed optimism about the approval and plans to work with the FDA on a path that includes clinical sites in the U.S. for a future Phase 3 pivotal study of PrimeC.

growth-positive

NeuroSense Therapeutics announced final results from a biomarker study conducted to evaluate the potential of its combination platform therapy for the treatment of Alzheimers disease (AD). The study showed that TDP-43, a novel biomarker, was elevated in AD patients compared to a healthy control group. NeuroSense plans to commence a Phase 2 double-blind proof-of-concept study in Alzheimers disease in the first half of 2023.

growth-positive

NeuroSense Therapeutics has received approval from the Italian Medicines Agency to commence patient enrollment in Italy for its Phase 2b clinical trial of its lead drug candidate PrimeC in the treatment of amyotrophic lateral sclerosis (ALS). The trial is currently enrolling patients in Israel and has received clearance from the U.S. Food and Drug Administration to open clinical sites for patient recruitment in the U.S. NeuroSense expects to enroll and dose the first patients in Italy and the U.S. in the next few weeks. PrimeC is a novel extended-release oral formulation composed of a unique fixed-dose combination of two FDA-approved drugs: ciprofloxacin and celecoxib. The drug aims to target key mechanisms of ALS to potentially inhibit its progression.

growth-positive

NeuroSense Therapeutics Ltd. announces its participation in three upcoming conferences: The 21st Annual NEALS Meeting, Neuroscience 2022, and the 33rd International Symposium on ALS/MND. The companys Chief Medical Officer and Head of Scientific Program will present posters on product development, biomarker research, and disease-modifying treatments for ALS. NeuroSenses VP Discovery & IP Generator will explore scientific collaborations and partnership opportunities at the conferences. The company is focused on developing treatments for neurodegenerative diseases and believes that these diseases represent a significant unmet medical need. NeuroSenses strategy is to develop combined therapies targeting multiple pathways associated with these diseases.

growth-positive

NeuroSense Therapeutics Ltd. announced its participation in the BIO-Europe Partnering Conference to explore potential collaboration and partnership opportunities in the field of neurology. The company is focused on discovering and developing treatments for neurodegenerative diseases such as ALS, Alzheimers, and Parkinsons. NeuroSense believes that these diseases represent a significant unmet medical need. The companys strategy is to develop combined therapies targeting multiple pathways associated with these diseases. NeuroSense will be attending the conference to meet with companies and evaluate assets from institutions and companies working on neurology indications.

growth-positive

NeuroSense Therapeutics announced the results of a biomarker study for its combination drug CogniC, which is being developed for the treatment of Alzheimers disease. The study identified several biomarkers associated with Alzheimers disease, indicating that CogniCs mechanism of action may be effective in targeting the pathways involved in the disease. The company plans to advance CogniC into clinical trials in 2023. NeuroSense is utilizing a cutting-edge technology called Neuron-Derived Exosomes to conduct the biomarker study non-invasively through blood samples. The study aims to evaluate the potential of CogniC in modulating the identified biomarkers. NeuroSense is a clinical-stage biotechnology company focused on developing treatments for neurodegenerative diseases.

growth-positive

NeuroSense Therapeutics has received FDA clearance to initiate a pharmacokinetic study of PrimeC, a treatment for ALS. PrimeC is a novel extended-release oral formulation composed of two FDA-approved drugs. The company plans to initiate a Phase IIb study in Q2 2022. NeuroSense is also advancing programs in Alzheimers disease and Parkinsons disease. The pharmacokinetic study aims to generate additional data on the bioavailability of PrimeC. NeuroSense recently announced a collaboration with Massachusetts General Hospital to determine the biological changes in ALS-related pathologies. ALS is an incurable neurodegenerative disease with a growing patient population.

growth-positive

NeuroSense Therapeutics has announced the grant of a key patent in Australia for its unique fixed-dose combination of ciprofloxacin and celecoxib, two drugs used in its lead development candidate for treating Amyotrophic Lateral Sclerosis (ALS). The patent, which was already granted in the US in 2021, will last until June 2038. NeuroSense plans to initiate its ALS Phase 2b study in May 2022. The company is focused on discovering and developing treatments for neurodegenerative diseases and has ongoing programs in Alzheimers disease and Parkinsons disease.

growth-positive

NeuroSense Therapeutics has announced the closing of its initial public offering (IPO) on the Nasdaq Capital Market. The company raised approximately $12 million in gross proceeds from the offering, with net proceeds of $9.9 million. The funds will be used to advance the clinical development of its lead product candidate for the treatment of ALS, as well as for preclinical research and development in support of potential investigational new drug applications for its product candidates targeting Alzheimers and Parkinsons. NeuroSense believes that neurodegenerative diseases represent a significant unmet medical need and aims to develop combined therapies targeting multiple pathways associated with these diseases. The IPO marks a significant milestone for the company in its mission to bring effective treatments to patients suffering from neurodegenerative diseases.

growth-positive

NeuroSense Therapeutics has publicly filed an F-1 Registration Statement with the U.S. Securities and Exchange Commission for a proposed initial public offering on the Nasdaq Capital Market. The number of securities and price range have not been determined yet. Maxim Group LLC is acting as the sole book-running manager for the offering.

growth-positive

נוירוסנס, an Israeli company, plans to IPO on NASDAQ to raise $30-40 million for developing a treatment for ALS, a severe neurodegenerative disease. The company conducted a successful small trial at Ichilov Hospital. CEO Alon Ben Nun mentioned that a major pharma company is closely interested in their research. This move is expected to positively impact the companys growth. The article also references a significant market reaction to Biogens FDA approval for Aduhelm, an Alzheimers treatment.

growth-positive

Israeli biotech company NeuroSense Therapeutics, which is developing a drug for ALS, has begun a pre-IPO fundraising round of $20 million. The companys value in the fundraising is $80 million before the money, reflecting a 6.6-fold increase in its value last March. Half of the current fundraising money is intended to complete a phase 2 clinical trial for the companys flagship drug, PrimeC, for the treatment of ALS patients. The rest will be diverted to drug trials for the treatment of neurodegenerative diseases Parkinsons and Alzheimers, and preparations for an initial offering on NASDAQ in the fourth quarter of the year.

growth-positive

NeuroSense Therapeutics, a biotech company, is reporting promising trends in their NST002 Phase IIa study for ALS progression. The study shows positive results in patients respiratory function and a reduced deterioration in ALSFRS-R score after 9 months of treatment with PrimeC. The study is set to be completed in January 2021, and all patients have requested to continue with the treatment. NeuroSense Therapeutics is a drug development company focused on developing oral treatments for ALS and other neurodegenerative diseases.

growth-positive

NeuroSense Therapeutics drug PrimeC shows potential to slow ALS progression and lung function decline, according to interim results from a Phase 2a clinical trial. The drug is a combination treatment of two existing medications, ciprofloxacin and celecoxib, and aims to treat inflammation of the nervous system and impaired regulation of RNA activity. NeuroSense plans to continue investigating PrimeC with additional analysis of the ongoing trial and launch another clinical study in early 2021. The company has received orphan drug status from the U.S. FDA. The article does not mention any specific partners, customers, valuation amount, acquisition amount, investment amount, layoffs, or date of the event.

growth-positive

NeuroSense Therapeutics announced that its drug PrimeC, aimed at slowing ALS progression, was safe and well tolerated in an interim analysis of a Phase IIa study. The study showed trends toward slowing disease progression in ALS patients. The company plans to continue the study for an additional 6 months and intends to initiate another clinical trial in 2021. The positive results from the study, along with promising preclinical results, warrant further investigation in a larger, placebo-controlled study. NeuroSense Therapeutics is a biotech company focused on developing ground-breaking oral treatments for ALS and other neurodegenerative diseases.

growth-positive

NeuroSense Therapeutics has initiated two clinical studies to evaluate the benefit of their drug PrimeC for ALS patients. The studies are being conducted in Israel and the USA and plan to enroll 45 patients. PrimeC has shown exceptional results in pre-clinical models of ALS, improving the swimming abilities of treated fish and indicating neuroprotective properties. The company aims to evaluate the drugs efficacy, ability to slow disease progression, and improve quality of life. NeuroSense has also received orphan drug designation from the FDA for PrimeC. ALS, also known as Lou Gehrigs disease, is a neurodegenerative disease affecting motor neurons. NeuroSense Therapeutics is a drug development company focused on ALS and other neurodegenerative diseases.

growth-positive

NeuroSense Therapeutics has raised NIS 4 million ($1.15 million) in a crowdfunding campaign, with 1,114 new investors collectively owning a 10% stake in the company. The funding will be used to complete the development of a drug for treating amyotrophic lateral sclerosis (ALS) and prepare for a phase II clinical trial. NeuroSense is the second company to surpass the $1 million mark using the Israeli crowdfunding platform Pipelbiz. ALS is a neurodegenerative disease that causes gradual paralysis and has a high mortality rate. NeuroSense aims to address this unmet medical need.

growth-positive

NeuroSense Therapeutics, an Israeli biotech company, is developing a treatment for ALS, a degenerative disease that attacks motor nerve cells. The company was founded two and a half years ago by CEO Alon Ben-Noon and has attracted investment from Ariel Gordon, whose wife has ALS, and Yossi Gross, whose sister died from the disease. The drug being developed by NeuroSense contains two ingredients that have already been tested and found to be safe for use on humans. The company, which has raised $1 million to date, hopes to begin a Phase II human trial in mid-2019.

growth-positive

Raanana drug development company NeuroSense Therapeutics is conducting pre-clinical research on a novel ALS treatment. The treatment, based on an antibiotic and an anti-inflammatory drug, has shown promising results in zebrafish studies. NeuroSense plans to commence clinical trials later this year in Israel and the United States to determine the effectiveness of the treatment in humans. The company aims to slow down or stop the progression of ALS and improve patient movement. NeuroSense has received support from leading clinicians and has donated a percentage of the company to the Israel ALS Research Association.

growth-positive

NeuroSense Therapeutics, led by CEO Alon Ben-Noon, is developing a treatment for ALS using a drug already used for a different disease. The company plans to enter a Phase Ib trial in the fourth quarter of the year to test safety and effectiveness. If successful, they will proceed to a Phase II/III trial. NeuroSense has received a $1 million grant and aims to raise $2 million. The article highlights the lack of effective treatment for ALS and the leniency of regulatory authorities in registering products for this disease. The company believes it can bring the drug to market within five years.